Embla Medical hf

EMBLA MEDICAL's next confirmed earnings release is scheduled for February 2, 2027.

As of June 30, 2026, EMBLA MEDICAL has 425.91M shares outstanding.

As of June 30, 2026, EMBLA MEDICAL maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.66, indicating elevated leverage, while an interest coverage ratio of 9.59 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, EMBLA MEDICAL posted a return on equity (ROE) of 10.36, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 7.12 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 5.38, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.45, useful for judging operating efficiency across full business cycles. The company generates approximately 235,396.90 in revenue per employee across its workforce of 4,163.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.35 indicates how many times EMBLA MEDICAL sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, EMBLA MEDICAL recorded 25.91M in income tax expense. That works out to an effective tax rate of 22.42, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 115.57M, leaving 89.00M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on August 28, 2026, EMBLA MEDICAL's stock has declined approximately 5.73% over the past 52 weeks. The 50-day moving average sits at 4.58, while the 200-day moving average is 5.70.

Over the twelve months ended June 30, 2026, EMBLA MEDICAL generated 980.08M in revenue and converted that into 89.00M in net income, yielding earnings per share of 0.21. EBITDA reached 192.04M, while operating income came in at 129.81M.

As of June 30, 2026, EMBLA MEDICAL holds 98.78M in cash and equivalents against 533.97M in total debt, resulting in a net debt position of 261.33M. Total book value stands at 920.63M, with working capital of 94.10M providing operational flexibility.

EMBLA MEDICAL produced 118.92M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -29.62M in capital expenditures, free cash flow totaled 89.30M - equivalent to 0.21 per share.

Over the twelve months ended June 30, 2026, EMBLA MEDICAL posted a gross margin of 62.20, reflecting its pricing power and cost economics. The operating margin of 13.25 and net profit margin of 9.08 provide insight into operational efficiency.

EMBLA MEDICAL's most recent stock split took place on September 8, 2005 with a 59:60 split ratio.